

## Flexible injection time when needed\*



## Once daily, morning or evening injection

Toujeo® can give your patients **sustained glycaemic control** when administered once daily in the **morning or evening**.<sup>\*1</sup>



### Now available in two pen options:



**Toujeo® DoubleStar™:**  
The **highest unit capacity** of any basal insulin pen on the market<sup>1-5</sup>



**Toujeo® DoubleStar™ is recommended for appropriate patients with diabetes mellitus who require at least 20 units of basal insulin per day.<sup>1</sup>**

T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

\*Observed in clinical studies conducted in adults with T1DM. The dose regimen (dose and timing) should be adjusted according to individual response.<sup>1</sup>

- 1-Toujeo® Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/6938/smpc>. [Accessed: June 2023].
2. Lantus® Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/2376/smpc>. [Accessed: June 2023].
3. Tresiba® Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/2944/smpc>. [Accessed: June 2023].
4. Levemir® Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/5536/smpc>. [Accessed: June 2023].
5. Pohlmeier H, et al. J Diabetes Sci Technol. 2017;11;263-269.